Endometrial
Conditions
Keywords
ERA
Brief summary
Do differences in endometrial gene expression exist after different protocols of endometrial preparation for embryo transfer? The recent apparition of endometrial receptive arrays technology let us know if endometrial is receptive or not in patients with some problems of infertility as implantation failure, for that we want to know if this technology would tell us if the different kind of protocols for endometrial preparation origin differences that could explain some of the founded results.
Detailed description
Do differences in endometrial gene expression exist after different protocols of endometrial preparation for embryo transfer? The clinical results in different publications showed different results, some of them described the natural cycle superior as the substituted cycles, and in contrast other large series showed superior results in substituted cycles than natural but with an increased of pregnancies losses. The recent apparition of endometrial receptive arrays technology let us know if endometrial is receptive or not in patients with some problems of infertility as implantation failure, for that we want to know if this technology would tell us if the different kind of protocols for endometrial preparation origin differences that could explain some of the founded results.
Interventions
PROCEDUREEndometrial Biopsy
4 endometrial biopsy
Sponsors
Igenomix
IVI Madrid
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 34 Years
Healthy volunteers
Yes
Inclusion criteria
* age between 18 and 35 years * regular menstrual cycles (between 25 and 35 days) * normal basal hormones(follicle-stimulating hormone \[FSH\] and LH \<10 IU/ mL and estradiol \<60 pg/mL) * normal karyotype * body massindex between 18 and 25 kg/m2 * negative serology * normal cervical cytology in the past year, and a vaginal ultrasound without evidence of any pathologic conditions
Exclusion criteria
* endometriosis * polycystic ovariansyndrome * use of an intrauterine device in the last 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Endometrial receptivity | 4 months | Total RNA was extracted using the TRIzol method according to the manufacturer's recommendations (Life Technologies). Approximately 1-2 mg of total RNA was obtained per milligram of endometrial tissue. The RNA quality was assessed by loading 300 ng of total RNA onto an RNA LabChip and was analyzed in an A2100 Bioanalyzer (Agilent Technologies). Only samples with a RNA integrity number \>7 were selected for microarray analysis. Sample preparation and hybridization was adapted from the Agilent technical manual. Hybridized microarrays were scanned in an Axon 4100A scanner (Molecular Devices), and the data were extracted with the GenePix Pro 6.0 software (Molecular Devices). The ERA microarray validation has been previously published. Reverse transcriptase-polymerase chain reaction (PCR) was performed for four selected up-regulated genes: GPX3, FXYD2, SPP1, and MT1G. The ERA gene expression values were preprocessed, normalized, and statistically analyzed. Briefly, the half background |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hormonal profile | LH,E2,P4 | Hormonal profile different dates of protocols |
Countries
Spain
Outcome results
None listed